Frederik Kier

Frederik Kier

Senior Vice President for region AAMEO

 

Mr. Frederik Kier you are the Senior Vice President for region AAMEO, can you shed some light on what this region is?

Region AAMEO is an Acronym for Asia, Africa, Middle East and Oceania. It is a big region with diverse cultures and a population of 4.5 billion people that we serve. In order to be closer to our stakeholders, we established presence in Dubai being a suitable, business encouraging and close hub. 

 

So what is Novo Nordisk all about Mr. Frederik?

In Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Diabetes poses one of today’s biggest global health challenges. We work for a future where fewer people get diabetes, everyone with diabetes is diagnosed, and everyone who is diagnosed receives adequate treatment and can live a life with as few limitations as possible.

Since the company was founded in Denmark more than 90 years ago, we have been changing diabetes. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

 

You have recently entered into the field of obesity care, what are your main aims?

Even though obesity has been classified as a disease by the WHO, it is still not widely regarded as such.  Novo Nordisk aims to ensure obesity is widely recognised as a chronic disease and that a clinically meaningful weight loss of 5–10% is acknowledged as a key contributor towards improving weight-related comorbidities (accompanying disease), such as type 2 diabetes and cardiovascular disease.

 

We heard a lot about recent initiatives carried out by Novo Nordisk, what is it all about?

Yes there are many worldwide but I would like to highlight two activities related to the UAE market. The UAE affiliate signed a memorandum of understanding with friends for diabetes society in collaboration with the Emirati Red Crescent where Novo Nordisk pledged to provide insulin treatment for 50 type 1 patients.

Also, we had a very special visit by Novo Nordisk’s CEO Lars Fruergaard Jørgensen where we engaged with several UAE key opinion leaders and stakeholders to strengthen and expand obesity care in the UAE.  These projects are part of our patient-centric focus where we can touch many lives and one of the many reasons that make us proud to work for Novo Nordisk.

 

Mads Bo Larsen, Corporate Vice President at Novo Nordisk

Ayman Hassan, Vice President and UAE General Manager at Novo Nordisk

3 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *